From: Association of human myxovirus resistance protein A with severity of COVID-19
Low-MxA < 400 μg/L (N = 36) | Intermediate MxA 400–799 μg/L (N = 73) | High MxA ≥ 800 μg/L (N = 159) | p-value | |
---|---|---|---|---|
Respiratory support, n/N (%) | < 0.001 | |||
No respiratory support | 22/36 (61%) | 26/73 (36%) | 28/158 (18%) | |
Supplemental oxygen (≤ 15 L/min) | 7/36 (19%) | 27/73 (37%) | 75/158 (48%) | |
HFNC/NIV/Intubation | 7/36 (19%) | 20/73 (27%) | 55/158 (35%) | |
ICU, n/N (%) | 0.329 | |||
No | 28/36 (78%) | 53/73 (73%) | 101/159 (64%) | |
Yes | 4/36 (11%) | 14/73 (19%) | 35/159 (22%) | |
DNR | 4/36 (11%) | 6/73 (8%) | 23/159 (15%) | |
Corticosteroids, n/N (%) | 17/36 (47%) | 45/73 (62%) | 123/159 (77%) | < 0.001 |
In hospital mortality, n/N (%) | 1/36 (3%) | 2/73 (3%) | 10/159 (6%) | 0.416 |